{'52WeekChange': 1.9196241,
 'SandP52WeekChange': 0.0644362,
 'address1': '215 First Street',
 'address2': 'Suite 200',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 27.99,
 'askSize': 1400,
 'averageDailyVolume10Day': 465337,
 'averageVolume': 684401,
 'averageVolume10days': 465337,
 'beta': 3.546388,
 'beta3Year': None,
 'bid': 27.96,
 'bidSize': 800,
 'bookValue': 7.544,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 28.46,
 'dayLow': 27.28,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -9.34,
 'enterpriseToRevenue': None,
 'enterpriseValue': 851805824,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '617 577 0472',
 'fiftyDayAverage': 30.904858,
 'fiftyTwoWeekHigh': 59.49,
 'fiftyTwoWeekLow': 6.01,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 29528474,
 'forwardEps': -3.07,
 'forwardPE': -9.110749,
 'fromCurrency': None,
 'fullTimeEmployees': 106,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.021459999,
 'heldPercentInstitutions': 0.9953,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/constellationpharma.com',
 'longBusinessSummary': 'Constellation Pharmaceuticals, Inc., a clinical-stage '
                        'biopharmaceutical company, discovers and develops '
                        'therapeutics to address serious unmet medical needs '
                        'in patients with cancers associated with abnormal '
                        'gene expression or drug resistance. Its lead product '
                        'candidates include CPI-0610 that is in Phase II '
                        'clinical trials for the treatment of patients with '
                        'myelofibrosis in combination with ruxolitinib; and '
                        'CPI-1205 that is in Phase Ib/II clinical trials for '
                        'metastatic castration-resistant prostate cancer in '
                        'combination with androgen receptor signaling '
                        'inhibitors. The company is also developing CPI-0209 '
                        'that is in Phase I dose escalation portion of a Phase '
                        'I/II clinical trial to treat solid tumors. The '
                        'company was formerly known as Epigenetix, Inc. and '
                        'changed its name to Constellation Pharmaceuticals, '
                        'Inc. in March 2008. Constellation Pharmaceuticals, '
                        'Inc. was founded in 2008 and is based in Cambridge, '
                        'Massachusetts.',
 'longName': 'Constellation Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 1328278528,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_44234400',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -91574000,
 'nextFiscalYearEnd': 1640908800,
 'open': 27.84,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '617 714 0555',
 'previousClose': 28.24,
 'priceHint': 2,
 'priceToBook': 3.707582,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 28.46,
 'regularMarketDayLow': 27.28,
 'regularMarketOpen': 27.84,
 'regularMarketPreviousClose': 28.24,
 'regularMarketPrice': 27.84,
 'regularMarketVolume': 293740,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 47489400,
 'sharesPercentSharesOut': 0.0883,
 'sharesShort': 4191014,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1573748,
 'shortName': 'Constellation Pharmaceuticals, ',
 'shortPercentOfFloat': 0.1292,
 'shortRatio': 4.6,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'CNST',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.849,
 'twoHundredDayAverage': 34.41223,
 'volume': 293740,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.constellationpharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02142'}